The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
Open accessAbstract
BACKGROUND: Previous studies have suggested that the use of nonsteroidal antiinflammatory drugs (NSAIDs) may help to prevent Alzheimer's disease. The results, however, are inconsistent. METHODS: We studied the association between the use of NSAIDs and Alzheimer's disease and vascular dementia in a prospective, population-based cohort study of 6989 subjects 55 years of age or older who were free of dementia at base line, in 1991. To detect new cases of dementia, follow-up screening was performed in 1993 and 1994 and again in 1997 through 1999. The risk of Alzheimer's disease was estimated in relation to the use of NSAIDs as documented in pharmacy records. We defined four mutually exclusive categories of use: nonuse, short-term use (1 month or less of cumulative use), intermediate-term use (more than 1 but less than 24 months of cumulative use), and long-term use (24 months or more of cumulative use). Adjustments were made by Cox regression analysis for age, sex, education, smoking status, and the use or nonuse of salicylates, histamine Hz-receptor antagonists, antihypertensive agents, and hypoglycemic agents. RESULTS: During an average follow-up period of 6.8 years, dementia developed in 394 subjects, of whom 293 had Alzheimer's disease, 56 vascular dementia, and 45 other types of dementia. The relative risk of Alzheimer's disease was 0.95 (95 percent confidence interval, 0.70 to 1.29) in subjects with short-term use of NSAIDs, 0.83 (95 percent confidence interval, 0.62 to 1.11) in those with intermediate-term use, and 0.20 (95 percent confidence interval, 0.05 to 0.83) in those with long-term use. The risk did not vary according to age. The use of NSAIDs was not associated with a reduction in the risk of vascular dementia. CONCLUSIONS: The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recognition that a robust inflammatory response contributes to AD also fuelled the discovery that long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) reduced the risk for AD, delayed disease onset, and slowed cognitive decline (McGeer et al., 1996;Stewart et al., 1997;in t' in t'Veld et al., 2001).”
From PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice (2012) · cites this paper as in t'Veld et al., 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Roth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Determinants of disease and disability in the elderly: The Rotterdam elderly study
Albert Hofman, D., Grobbee, D. E., de Jong, P. T. V. M., & Ouweland, F. A. V. D. (1991) · European Journal of Epidemiology · doi:10.1007/bf00145007 · Cited by 1,120
Flagged first, then by citations
Research works printed but not linked: 4
- Brooks W, 1998, Neurobiol Aging, 19, S140
- Kukull WA, 1994, Neurology, 44, A237
- Cornelius C, 1998, Neurobiol Aging, 19, S28
- Time-varying explanatory variables. In: Clayton D, Hills M. Statistical models in epidemiology. Oxford, England: Oxford University Press, 1993:307-18.
Cited by
Sorted by citations
Items 501–600 of 1,000
McFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
Nagano, S., Huang, X., Moir, R. D., Payton, S. M., Tanzi, R. E., & Bush, A. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313003200 · Cited by 48
Engelhardt, E., Brucki, S. M. D., Cavalcanti, J. L. D. S., Forlenza, O. V., Laks, J., & Vale, F. A. C. (2005) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2005000600035 · Cited by 46
Ali, Y., Kitay, B. M., & Zhai, R. G. (2010) · Molecules · doi:10.3390/molecules15106859 · Cited by 49
Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship
Bettcher, B. M., & Kramer, J. H. (2012) · Neurocase · doi:10.1080/13554794.2011.654227 · Cited by 49
Mechanisms of Risk Reduction in the Clinical Practice of Alzheimer’s Disease Prevention
Schelke, M. W., Attia, P., Palenchar, D. J., Kaplan, B., Mureb, M., Ganzer, C. A., Scheyer, O., Rahman, A., Kachko, R., Krikorian, R., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00096 · Cited by 52
“Clinical studies reveal elevated serum levels of inflammatory cytokines [particularly TNF-a (Álvarez et al., 2007) and IL-6 (Hüll et al., 1996)] in patients with AD and reduction of AD risk with long-term use of COX-inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) (In t’ Veld et al., 2001).”
BackgroundInflammation and dementia: epidemiologic evidence
Peila, R., & Launer, L. J. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00693.x · Cited by 47
Self-citationNo improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H., Bulic, B., Schneider-Axmann, T., Bayer, T. A., Weggen, S., & Wirths, O. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.006 · Cited by 46
“There is substantial epidemiological evidence that users of NSAIDs have a decreased risk of developing AD (in t’ Veld et al., 2001; Szekely and Zandi, 2010; Vlad et al., 2008).”
BackgroundColostrinin™: An Oxidative Stress Modulator for Prevention and Treatment of Age-related Disorders
Boldogh, I. R., & Kruzel, M. L. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13308 · Cited by 45
“inflammatory drugs have been tested in various preventive protocols [57,120].”
The cAMP-specific phosphodiesterase 4B mediates Aβ-induced microglial activation
Sebastiani, G., Morissette, C., Lagacé, C., Boulé, M., Ouellette, M., McLaughlin, R. W., Lacombe, D., Gervais, F., & Tremblay, P. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.024 · Cited by 45
Alzheimer’s Disease and Genetics of Inflammation: A Pharmacogenomic Vision
Vasto, S., Candore, G., Duro, G., Lio, D., Grimaldi, M. P., & Caruso, C. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.12.1735 · Cited by 46
Blasko, I., Kemmler, G., Krampla, W. W., Jungwirth, S., Wichart, I., Jellinger, K. A., Tragl, K. H., & Fischer, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.006 · Cited by 46
Role of Traditional Nonsteroidal Anti-inflammatory Drugs in Alzheimer’s Disease
Gupta, P. P., Pandey, R. D., Jha, D., Shrivastav, V. K., & Kumar, S. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514542644 · Cited by 46
The influence of brain inflammation upon neuronal adenosine A2Breceptors
Rosi, S., McGann, K., Hauss‐Wegrzyniak, B., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01825.x · Cited by 45
“Therefore, it is not surprising that conventional non-steroidal anti-inflammatory drugs (NSAIDs) may slow the progress or delay the onset of AD (McGeer and McGeer 1999; in ‘T Veld et al. 2001).”
BackgroundRahman, S. M. A., van Dam, A., Schultzberg, M., & Crisby, M. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.07.018 · Cited by 45
Hüll, M., Müksch, B., Akundi, R. S., Waschbisch, A., Hoozemans, J. J. M., Veerhuis, R., & Fiebich, B. L. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.08.013 · Cited by 47
Risk Factors for Alzheimer Dementia in a Community-Based Birth Cohort at the Age of 75 Years
Fischer, P. A., Zehetmayer, S., Jungwirth, S., Weissgram, S., Krampla, W., Hinterberger, M., Torma, S., Rainer, M. K., Huber, K. R., Hönigschnabl, S., et al. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000128577 · Cited by 45
Hormone therapy and Alzheimer?s disease: benefit or harm?
Henderson, V. W. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.2.389 · Cited by 46
Waldstein, S. R., Wendell, C. R., Seliger, S. L., Ferrucci, L., Metter, E. J., & Zonderman, A. B. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02618.x · Cited by 44
The chiral switch: the development of single enantiomer drugs from racemates.
Hutt, A. J., & Valentová, J. (2003) · Research Portal (King's College London) · Cited by 44
Newby, D., Prieto‐Alhambra, D., Duarte‐Salles, T., Ansell, D., Pedersen, L. H., van der Lei, J., Mosseveld, M., Rijnbeek, P. R., James, G., Alexander, M., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00606-5 · Cited by 45
PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42
Boutaud, O. G., Montine, T. J., Chang, L., Klein, W. L., & Oates, J. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03586.x · Cited by 44
“…disease (AD) may be inferred from two large prospective studies on individuals with no baseline dementia that found a 60–80% reduction in risk of developing AD associated with the use of non-steroidal antiinflammatory drugs for at least 2 years (Stewart et al. 1997; in ¢t Veld et al. 2001).”
BackgroundPrevention of brain aging and dementia
Ball, L. J., & Birge, S. J. (2002) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00027-7 · Cited by 42
Thalidomide-based TNF-α inhibitors for neurodegenerative diseases
Greig, N. H., Giordano, T., Zhu, X., Yu, Q., Perry, T., Holloway, H. W., Brossi, A. R., Rogers, J. T., Sambamurti, K., & Lahiri, D. K. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1486 · Cited by 44
Bulic, B., Neß, J., Hahn, S., Rennhack, A., Jumpertz, T., & Weggen, S. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376352 · Cited by 43
Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice
Subaiea, G. M., Adwan, L. I., Ahmed, A. H., Stevens, K. E., & Zawia, N. H. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.002 · Cited by 45
Kern, S., Skoog, I. G., Östling, S., Kern, J., & Börjesson‐Hanson, A. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001288 · Cited by 43
Song, L., Chen, J., Lo, C. Z., Guo, Q., Feng, J., & Zhao, X. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104175 · Cited by 43
Vasconcelos, A. R., Kinoshita, P. F., Yshii, L., Orellana, A. M., Böhmer, A. E., Lima, L. D. S., Alves, R., Andreotti, D. Z., Marcourakis, T., Scavone, C., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.02.020 · Cited by 42
Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice
Barroso, E., del Valle, J., Porquet, D., Santos, A. M. V., Salvadó, L., Rodríguez‐Rodríguez, R., Gutiérrez, P., Anglada‐Huguet, M., Alberch, J., Camins, A., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.006 · Cited by 42
“In fact, in addition to neurodegeneration, AD also shows a significant inflammatory component [16] and epidemiological studies have revealed that the use of non-steroidal anti-inflammatory drugs (NSAIDs) dramatically reduce the risk for AD [17], suggesting that antiinflammatory treatments could be beneficial to AD pat…”
BackgroundInterleukin‐1A (−889) genetic polymorphism increases the risk of multiple system atrophy
Combarros, O., Infante, J., Llorca, J., et al. (2003) · Movement Disorders · doi:10.1002/mds.10540 · Cited by 42
Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
Castellani, R. J., Zhu, X., Lee, H., Moreira, P. I., Perry, G. L., & Smith, M. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.5.473 · Cited by 42
Molecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease
Gandy, S., Martins, R. N., & Buxbaum, J. D. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200310000-00011 · Cited by 41
Tong, H., Zhang, X., Meng, X., Xu, P., Zou, X., & Qu, S. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.01.017 · Cited by 42
Progress in the development of new drugs in Alzheimer's disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0012-x · Cited by 32
Araya‐Quintanilla, F., Gutiérrez‐Espinoza, H., Sánchez-Montoya, U., Muñoz-Yánez, M. J., Baeza-Vergara, A., Petersen-Yanjarí, M., & Fernández-Lecaros, L. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2017.07.014 · Cited by 41
Yin, J., Turner, G. H., Lin, H.-J., Coons, S. W., & Shi, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110479 · Cited by 41
“Suppression of inflammation response may prevent or delay the initial onset of AD symptoms [30–32].”
BackgroundTakata, K., Kitamura, Y., Tsuchiya, D., Kawasaki, T., Taniguchi, T., & Shimohama, S. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00447-6 · Cited by 41
Piperazinyl pyrimidine derivatives as potent γ-secretase modulators
Rivkin, A., Ahearn, S. P., Chichetti, S. M., Kim, Y. R., Li, C., Rosenau, A., Kattar, S. D., Jung, J. O., Shah, S., Hughes, B. L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.101 · Cited by 41
Inflammation in Neurodegenerative Disorders: Friend or Foe?
Galimberti, D., Fenoglio, C., & Scarpini, E. A. (2008) · Current Aging Science · doi:10.2174/1874609810801010030 · Cited by 41
Lacombe, P., Mathews, P. M., Schmidt, S., Breidert, T., Heneka, M., Landreth, G., Feinstein, D. L., & Galea, E. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-11 · Cited by 179
“This idea was in accordance with the view that chronic inflammation contributes to the pathogenesis of Alzheimer's disease [for review, [13]], as supported by: i) epidemiological studies showing that the use of non steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen delays the onset of Alzheimer's disease [ 14 ]…”
Pharmacotherapeutic approaches to the prevention of Alzheimer's disease
Standridge, J. B. (2004) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/s1543-5946(04)90017-7 · Cited by 41
Bigler, E. D., Tate, D. F., Miller, M. J., Rice, S. A., Hessel, C. D., Earl, H. D., Tschanz, J. T., Plassman, B. L., & Welsh-Bohmer, K. A. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702870072 · Cited by 41
Arakawa, K., Arakawa, H., Hueston, C. M., & Deak, T. (2014) · Neuroendocrinology · doi:10.1159/000368606 · Cited by 40
Isolevuglandin Adducts in Disease
Salomon, R. G., & Bi, W.-Z. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6154 · Cited by 40
Subacute ibuprofen treatment rescues the synaptic and cognitive deficits in advanced-aged mice
Rogers, J. T., Liu, C., Zhao, N., Wang, J., Putzke, T., Yang, L., Shinohara, M., Fryer, J. D., Kanekiyo, T., & Bu, G. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.001 · Cited by 39
Araya‐Quintanilla, F., Gutiérrez‐Espinoza, H., Sánchez-Montoya, U., Muñoz-Yánez, M. J., Baeza-Vergara, A., Petersen-Yanjarí, M., & Fernández-Lecaros, L. (2017) · Neurología · doi:10.1016/j.nrl.2017.07.009 · Cited by 42
Inflammation: A Major Target for Compounds to Control Alzheimer’s Disease
Maccioni, R. B., Navarrete, L. P., González, A., González-Canacer, A., Guzmán‐Martínez, L., & Cortés, N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191014 · Cited by 42
Kosloski, L. M., Ha, D. M., Hutter-Saunders, J. A. L., Stone, D. K., Pichler, M. R., Reynolds, A. D., Gendelman, H. E., & Mosley, R. L. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06834.x · Cited by 40
Ko, C., Chu, Y., Narumiya, S., Chi, J.-Y., Furuyashiki, T., Aoki, T., Wang, S., Chang, W., & Wang, J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.020 · Cited by 40
Curcumin Derivatives Inhibit or Modulate Beta-Amyloid Precursor Protein Metabolism
Narlawar, R., Baumann, K., Schubenel, R., & Schmidt, B. (2007) · Neurodegenerative Diseases · doi:10.1159/000101832 · Cited by 39
Prevention of Alzheimer's disease
Szekely, C. A., Breitner, J. C. S., & Zandi, P. P. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797944 · Cited by 41
Lipoprotein‐associated phospholipase A2 is associated with risk of dementia
van Oijen, M., van der Meer, I. M., Albert Hofman, D., Witteman, J. C. M., Koudstaal, P. J., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20721 · Cited by 40
Self-citationMannila, A., Rautio, J., Lehtonen, M., Järvinen, T., & Savolainen, J. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.10.004 · Cited by 40
Lee, H., Villacreses, N., Rapoport, S., & Rosenberger, T. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02786.x · Cited by 41
“Longitudinal studies with non-steroidal anti-inflammatory drugs (NSAIDs) (Stewart et al. 1997; in ‘t Veld et al. 1998, 2001) and attenuation of microglia activation with COX-2 inhibitors in this model of neuroinflammation (Willard et al. 2000), which exert their effect by inhibiting prostaglandin…”
BackgroundCellular transcriptional alterations of peripheral blood in Alzheimer’s disease
Song, L., Yang, Y., Guo, Q., & Zhao, X. (2022) · BMC Medicine · doi:10.1186/s12916-022-02472-4 · Cited by 40
Staging anti-inflammatory therapy in Alzheimer’s disease
Lichtenstein, M. P. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00142 · Cited by 39
Hoshino, T., Namba, T., Takehara, M., Murao, N., Matsushima, T., Sugimoto, Y., Narumiya, S., Suzuki, T., & Mizushima, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07567.x · Cited by 40
Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 44
Switching from astrocytic neuroprotection to neurodegeneration by cytokine stimulation
Efremova, L. V., Chovancova, P., Adam, M., Gutbier, S., Schildknecht, S., & Leist, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1702-2 · Cited by 39
Personalized genetics of the cholinergic blockade of neuroinflammation
Simchovitz, A., Heneka, M. T., & Soreq, H. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13928 · Cited by 39
“The diminished risk of AD among users of non-steroidal antiinflammatory drugs (in t’ veld et al. 2001; Wang et al. 2015) attests to its importance, but steroids do not exert a similar effect; which calls for a closer inspection of the neuroinflammatory pathway in AD (Heneka et al. 2015a,c; Wang et…”
BackgroundGauthier, S. G., Zhang, H., Ng, K. P., Pascoal, T. A., & Rosa‐Neto, P. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0117-9 · Cited by 42
“Epidemiological studies further suggest that non-steroidal anti-inflammatory drugs (NSAIDS) can defer or prevent the onset of AD [84, 85].”
Neuroinflammatory Cytokines - The Common Thread in Alzheimer Pathogenesis
Griffin, W. S. T., Barger, S. W., & Chairman, D. P. A. V. (2011) · European Neurological Review · doi:10.17925/enr.2011.06.02.89 · Cited by 39
Lowering the risk of Alzheimer's disease: Evidence‐based practices emerge from new research
Jedrziewski, M. K., Lee, V. M. ‐., & Trojanowski, J. Q. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.09.007 · Cited by 41
Kitamura, Y., Shibagaki, K., Takata, K., Tsuchiya, D., Taniguchi, T., Gebicke-Haerter, P. J., Miki, H., Takenawa, T., & Shimohama, S. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.92.115 · Cited by 39
Ikezu, T., Luo, X., Weber, G. A., Zhao, J., McCabe, L., Buescher, J. L., Ghorpade, A., Zheng, J., & Xiong, H. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01739.x · Cited by 39
“Moreover, deactivation of microglia has implications for therapy since long-term treatment of affected patients with non-steroidal anti-inflam- matory drugs (NSAID) has been shown to retard the development and progression of AD (in ‘t Veld et al. 2001).”
BackgroundSystemic inflammation as a central player in the initiation and development of Alzheimer’s disease
Bayraktaroğlu, I., Ortí-Casañ, N., Dam, D. V., Deyn, P. P. D., & Eisel, U. L. M. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00529-5 · Cited by 49
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
Golde, T. E., Streit, W. J., & Chakrabarty, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt178 · Cited by 39
Ohnishi, A., Senda, M., Yamane, T., et al. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.04.008 · Cited by 38
Wen, M. M., Ismail, N. I. K., Nasra, M. M. A., & El-Kamel, A. H. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1937383 · Cited by 38
Patel, B. K., Hanna‐Brown, M., Hadley, M. R., & Hutt, A. J. (2004) · Electrophoresis · doi:10.1002/elps.200405928 · Cited by 38
(Re)building the nervous system: A review of neuron–glia interactions from development to disease
Demmings, M. D., Chagas, L. D. S., Traetta, M. E., Rodrigues, R. S., Acutain, M. F., Barykin, E. P., Datusalia, A. K., German‐Castelan, L., Mattera, V. S., Mazengenya, P., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16258 · Cited by 44
Can peripheral leukocytes be used as Alzheimer’s disease biomarkers?
Rezai-Zadeh, K. P., Gate, D., Szekely, C. A., & Town, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.118 · Cited by 36
Current Therapeutic Targets for Alzheimer's Disease
Chaudhary, A., Maurya, P. K., Yadav, B. S., Singh, S., & Mani, A. (2018) · Journal of Biomedicine · doi:10.7150/jbm.26783 · Cited by 39
Allen, S. P., Seehra, R. S., Heath, P. R., Hall, B., Bates, J., Garwood, C. J., Matuszyk, M. M., Wharton, S. B., & Simpson, J. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218028 · Cited by 42
“However, while epidemiological studies originally linked the use of non-steroidal anti-inflammatory drugs with a reduced risk of cognitive decline in AD [59], it should be noted that more recent clinical trials suggest this treatment does not slow down the progression of dementia [60].”
BackgroundThe Vascular-Immune Hypothesis of Alzheimer’s Disease
Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 39
Shie, F., Montine, K. S., BREYER, R. M., & Montine, T. J. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00509.x · Cited by 37
Dementia / Alzheimer's Disease
Lindsay, J., & Anderson, L. (2004) · BMC Women s Health · doi:10.1186/1472-6874-4-s1-s20 · Cited by 41
The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia
Janssen, J. C., Godbolt, A. K., Ioannidis, P., et al. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0296-4 · Cited by 37
“Central OCB in degenerative dementia are not unexpected given increasing evidence for the role of inflammation in these diseases [ 9 ] and future immunoblotting studies may be helpful to identify target antigens, e. g. abnormally folded proteins .A n alternative explanation would be that CNS specific OCB are related t…”
BackgroundTenenbaum, M., Azab, A. N., & KAPLANSKI, J. (2007) · Journal of Endotoxin Research · doi:10.1177/0968051907080428 · Cited by 37
Treatments for Alzheimer Disease
Potyk, D. K. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166671.86815.c1 · Cited by 37
Inflammation in parkinson’s disease
Hald, A., van Beek, J., & Lotharius, J. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_12 · Cited by 37
What's different about older people
Crome, P. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00253-1 · Cited by 37
Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: A pharmacogenomic approach
Candore, G., Balistreri, C. R., Grimaldi, M. P., Listı̀, F., Vasto, S., Chiappelli, M., Licastro, F., Colonna‐Romano, G., Lio, D., & Caruso, C. (2006) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.013 · Cited by 37
Alcohol consumption and risk of dementia
Liedholm, H., & Linné, A. B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09650-2 · Cited by 37
Aspartic Proteases Involved in Alzheimer's Disease
Schmidt, B. (2003) · ChemBioChem · doi:10.1002/cbic.200200532 · Cited by 38
Combination therapy in a transgenic model of Alzheimer's disease
Aytan, N., Choi, J., Carreras, I., Kowall, N. W., Jenkins, B. G., & Dedeoglu, A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.10.001 · Cited by 37
Khan, K. M., Balasubramanian, N., Gaudencio, G., Wang, R., Selvakumar, G. P., Kolling, L. J., Pierson, S. R., Tadinada, S. M., Abel, T. G., Hefti, M. M., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01546-5 · Cited by 37
Hieke, M., Neß, J., Steri, R., Dittrich, M., Greiner, C., Werz, O., Baumann, K., Schubert‐Zsilavecz, M., Weggen, S., & Zettl, H. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1003073 · Cited by 36
Paraoxonase 1 gene polymorphisms and dementia in humans
Helbecque, N., Cottel, D., Codron, V., Berr, C., & Amouyel, P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.100 · Cited by 36
Kim, W.-K., Jang, P., Woo, M.-S., Han, I.-O., Piao, H. Z., Lee, K., Lee, H., Joh, T. H., & Kim, H.-S. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.03.019 · Cited by 36
Biological Markers in Alzheimer Disease
Neugroschl, J. A., & Davis, K. L. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200211000-00005 · Cited by 37
Changing the Course of Alzheimer's Disease
Christensen, D. D. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0106 · Cited by 37
Morris, J. C. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200310000-00010 · Cited by 36
El‐Magd, M. A., Khalifa, S. F., Alzahrani, F. A., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.014 · Cited by 35
Yanguas‐Casás, N., Torres‐Fuentes, C., Crespo‐Castrillo, A., Díaz-Pacheco, S., Healy, K., Stanton, C., Chowen, J. A., García‐Segura, L. M., Arévalo, M., Cryan, J. F., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105495 · Cited by 36
Farı́as, G. G., Godoy, J. A., Vázquez, M. C., Adani, R., Meshulam, H., Ávila, J., Amitai, G., & Inestrosa, N. C. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.012 · Cited by 35
“On the other hand, a clinical study demonstrated that the use of non-steroidal antiinflammatory drugs (NSAIDs) reduce by 5-fold the risk for AD (Int’ Veld et al., 2001).”
BackgroundPurine derivatives as potent γ-secretase modulators
Rivkin, A., Ahearn, S. P., Chichetti, S. M., Hamblett, C. L., Garcia, Y., Martinez, M., Hubbs, J. L., Reutershan, M. H., Daniels, M. H., Siliphaivanh, P., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.02.008 · Cited by 35
Schultheiß, C., Blechert, B., Gaertner, F. C., Drecoll, E., Mueller, J., Weber, G. F., Drzezga, A. E., & Essler, M. (2006) · Angiogenesis · doi:10.1007/s10456-006-9030-4 · Cited by 35
Andrade, C., Singh, N. M., Thyagarajan, S., Nagaraja, N., Rao, N. S. K., & Chandra, J. S. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.08.009 · Cited by 34
Metadata
- Authors
- in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C.
- Affiliations
- Erasmus MC (NL)
- National Institutes of Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-11-22
- Volume
- 345
- Issue
- 21
- Pages
- 1515-1521
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2083556882
- Semantic Scholar
- 29c01ac52ec50618ec7b3b87ca55b707ca397434
- Cited by
- 1,196
- References
- 44
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 18 · 2023: 23 · 2022: 26 · 2021: 33 · 2020: 23 · 2019: 40 · 2018: 38 · 2017: 28 · 2016: 40 · 2015: 49 · 2014: 49 · 2013: 39 · 2012: 50
- FWCI
- 52.61
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- nonsteroidal anti-inflammatory drugs, Alzheimer's disease, vascular dementia, dementia risk, long-term NSAID use, older adults
- MeSH terms
- Aged, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, Risk, Salicylates, Dementia, Vascular, Cohort Studies, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
